{"classification":[{"coding":[{"code":"B01A","system":"http://www.whocc.no/atc/example"}]}],"combinedPharmaceuticalDoseForm":{"coding":[{"code":"tablet","system":"http://example.org.uk/fhir/dosefom"}]},"contained":[{"for":[{"reference":"#"}],"id":"EquilidoniumPhosphate","resourceType":"Ingredient","role":{"coding":[{"code":"active","system":"http://example.org.uk/fhir/ingredientType"}]},"status":"active","substance":{"code":{"concept":{"coding":[{"code":"123456","display":"Equilidonium Phosphate","system":"http://example.org.uk/fhir/substances"}]}},"strength":[{"presentationRatio":{"denominator":{"unit":"tablet","value":1},"numerator":{"code":"mL","system":"http://unitsofmeasure.org","unit":"ml","value":22}}}]}},{"for":[{"reference":"#"}],"id":"CalciumCarbonate","resourceType":"Ingredient","role":{"coding":[{"code":"excipient","system":"http://example.org.uk/fhir/ingredientType"}]},"status":"active","substance":{"code":{"concept":{"coding":[{"code":"456789","display":"Calcium Carbonate","system":"http://example.org.uk/fhir/substances"}]}},"strength":[{"presentationRatio":{"denominator":{"unit":"tablet","value":1},"numerator":{"code":"mL","system":"http://unitsofmeasure.org","unit":"ml","value":3}}}]}}],"crossReference":[{"product":{"reference":{"reference":"MedicinalProductDefinition/genericEquilidonium"}}}],"id":"equilidem-with-ing-and-auth","identifier":[{"system":"http://example.org.uk/fhir/product","value":"Equilidem25"}],"indication":"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.","legalStatusOfSupply":{"coding":[{"code":"POM","display":"Prescription only medicine","system":"http://example.org.uk/fhir/legalstatusofsupply"}]},"name":[{"productName":"Equilidem 2.5 mg film-coated tablets"}],"operation":[{"organization":[{"display":"EquiliDrugCo Processing Inc."}]}],"resourceType":"MedicinalProductDefinition","text":{"div":"
\n\t\t\t\t\n\t\t\t\t\tGenerated Narrative\n\t\t\t\t\n\t\t\t
\n\t\t\t\n\t\t\t\t\n\t\t\t\t\tId\n\t\t\t\t\n\t\t\t\t: equilidem-with-ing-and-auth\n\t\t\t
\n\t\t\t\n\t\t\t\t\n\t\t\t\t\tIdentifier\n\t\t\t\t\n\t\t\t\t: Equilidem25\n\t\t\t
\n\t\t\t\n\t\t\t\t\n\t\t\t\t\tCombined Pharmaceutical Dose Form\n\t\t\t\t\n\t\t\t\t:\n\t\t\t\t\n\t\t\t\t\ttablet\n\t\t\t\t\n\t\t\t
\n\t\t\t\n\t\t\t\t\n\t\t\t\t\tIndication\n\t\t\t\t\n\t\t\t\t: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n\t\t\t
\n\t\t\t\n\t\t\t\t\n\t\t\t\t\tLegal Status Of Supply\n\t\t\t\t\n\t\t\t\t:\n\t\t\t\t\n\t\t\t\t\tPrescription only medicine\n\t\t\t\t\n\t\t\t
\n\t\t\t\n\t\t\t\t\n\t\t\t\t\tclassification\n\t\t\t\t\n\t\t\t\t:\n\t\t\t\t\n\t\t\t\t\tB01A\n\t\t\t\t\n\t\t\t
\n\t\t\t\n\t\t\t\t\n\t\t\t\t\tIngredients\n\t\t\t\t\n\t\t\t\t:\n\t\t\t
\n\t\t\t\n\t\t\t\t\n\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tRole\n\t\t\t\t\t\n\t\t\t\t\t:\n\t\t\t\t\t\n\t\t\t\t\t\tactive\n\t\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tsubstance\n\t\t\t\t\t\t\n\t\t\t\t\t\t:\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEquilidonium Phosphate\n\t\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t-\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tPresentation\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t \n\t\t\t\t\t\n\t\t\t\t\t\t\t\t*\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t22 ml/1 tablet\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tRole\n\t\t\t\t\t\n\t\t\t\t\t:\n\t\t\t\t\t\n\t\t\t\t\t\texcipient\n\t\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tsubstance\n\t\t\t\t\t\t\n\t\t\t\t\t\t:\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCalcium Carbonate\n\t\t\t\t\t\t\n\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t-\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tPresentation\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t \n\t\t\t\t\t\n\t\t\t\t\t\t\t\t*\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t3 ml/tablet\n\t\t\t\t\t\t\t \n\t\t\t\t\t\t
\n\t\t\t\t\t\t-\n\t\t\t\t\t | \n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tProductName\n\t\t\t\t\t\t\n\t\t\t\t\t | \n\t\t\t\t
\n\t\t\t\t\t\t*\n\t\t\t\t\t | \n\t\t\t\t\t\n\t\t\t\t\t\tEquilidem 2.5 mg film-coated tablets\n\t\t\t\t\t | \n\t\t\t\t
\n\t\t\t\t\t\t-\n\t\t\t\t\t | \n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tProduct\n\t\t\t\t\t\t\n\t\t\t\t\t | \n\t\t\t\t
\n\t\t\t\t\t\t*\n\t\t\t\t\t | \n\t\t\t\t\t\n\t\t\t\t\t\tLink to generic equivalent\n\t\t\t\t\t | \n\t\t\t\t
\n\t\t\t\t\t\t-\n\t\t\t\t\t | \n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tManufacturer\n\t\t\t\t\t\t\n\t\t\t\t\t | \n\t\t\t\t
\n\t\t\t\t\t\t*\n\t\t\t\t\t | \n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEquiliDrugCo Processing Inc.\n\t\t\t\t\t\t\n\t\t\t\t\t | \n\t\t\t\t